Core Viewpoint - The company primarily focuses on the sales of third-generation insulin, while also developing a fourth-generation insulin product, GZR4, which aims to improve patient adherence and quality of life by significantly reducing injection frequency [2]. Group 1: Company Insights - The company, Ganli Pharmaceutical, is currently emphasizing the sales of third-generation insulin products [2]. - GZR4 injection is an innovative first-class therapeutic biological product under development, classified as a fourth-generation insulin weekly formulation [2]. - The fourth-generation insulin is expected to allow for weekly subcutaneous injections, providing stable blood glucose control and reducing the risk of hypoglycemia [2]. Group 2: Industry Context - Diabetes is a chronic disease requiring long-term medication, with insulin being a critical component of treatment [2]. - The market for insulin is primarily dominated by daily formulations, which account for a significant portion of the insulin market [2]. - Compared to daily formulations, the weekly insulin formulation is projected to reduce injection frequency by over 80%, potentially decreasing the number of injections by more than 300 times per year for patients [2].